We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET/CT in Psoriatic Arthritis

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01654198
First Posted: July 31, 2012
Last Update Posted: November 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Pennsylvania
  Purpose
When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.

Condition Intervention
Psoriatic Arthritis Radiation: FDG-PET/CT scan

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses. [ Time Frame: At the discretion of the PI ]

Secondary Outcome Measures:
  • Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP. [ Time Frame: At the discretion of the PI ]

Biospecimen Retention:   Samples With DNA
Plasma, Serum, and Plasma Cells

Estimated Enrollment: 18
Actual Study Start Date: July 2012
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Psoriatic arthritis Radiation: FDG-PET/CT scan
FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with psoriatic arthritis defined by CASPAR criteria and active joint disease.
Criteria

Inclusion Criteria:

  • Age 18-80,
  • active psoriatic arthritis (joint or enthesis inflammation)

Exclusion Criteria:

  • Diabetes,
  • pregnant,
  • no active PsA
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01654198


Locations
United States, Pennsylvania
University of Pennsylvania Division of Rheumatology
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Alexis R Ogdie, MD, MSCE University of Pennsylvania
  More Information

Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01654198     History of Changes
Other Study ID Numbers: 815253
First Submitted: July 27, 2012
First Posted: July 31, 2012
Last Update Posted: November 14, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases